Moreover, FASN inhibitors can block palmitoylation and plasma membrane- and mitochondria-associated EGFR activation and enhance cancer cell sensitivity to EGFR inhibitors by promoting EGFR ubiquitination, which further results in attenuating tumor growth (33, 34). This evidence concerns the gene FASN and cancer.